Verrica Pharmaceuticals Inc

NASDAQ:VRCA  
11.42
-0.05 (-0.44%)
Products, Strategic Combinations, Regulatory

Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co To Develop VP-102 For Molluscum And Common Warts In Japan

Published: 03/17/2021 11:49 GMT
Verrica Pharmaceuticals Inc (VRCA) - Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co.
, Ltd.
to Develop and Commercialize Vp-102 for Molluscum and Common Warts in Japan.
Verrica Pharmaceuticals - Under Deal, Torii Will Make an Up-front Payment of $11.5 Million.
Verrica Pharmaceuticals - Torii is Responsible for All Development Activities and Costs in Support of Obtaining Regulatory Approval in Japan.
Verrica Pharmaceuticals Inc - Vp-102, is Currently Under U.S. FDA Review for Treatment of Molluscum, With a PDUFA Goal Date of June 23, 2021.